Document is current
Any future updates will be listed below
-
Authors
Ishihara, Tomohiko
Koyama, Akihide
Atsuta, Naoki
Tada, Mari
Toyoda, Saori
Kashiwagi, Kenta
Hirokawa, Sachiko
Hatano, Yuya
Yokoseki, Akio
Nakamura, Ryoichi
Tohnai, Genki
Izumi, Yuishin
Kaji, Ryuji
Morita, Mitsuya
Tamura, Asako
Kano, Osamu
Aoki, Masashi
Kuwabara, Satoshi
Kakita, Akiyoshi
Sobue, Gen
Onodera, Osamu
-
Funding
Funding for this research was provided by:
Scientific Research from the Japan Society for the Promotion of Science (17K09750)
Scientific Research from the Japan Society for the Promotion of Science (21K07272)
Mitsubishi Tanabe Pharma
Japan ALS Association
Japan Agency for Medical Research and Development (17ek0109284h0001, 17ek0109284h0001, 17ek0109284h0001)
Scientific Research on Innovative Areas from MEXT (26117006)
MHLW Research on rare and intractable diseases Program (JPMH23FC1008)
- License Information
-
More Information
Article History
Received: 7 July 2024
Accepted: 9 October 2024
First Online: 6 November 2024
Declarations
:
: Ethical approval was obtained from the research ethics committees of Niigata University (G2015-0781, G2020-0031) in accordance with the Declaration of Helsinki. ALS cases and their spouses participating in JaCALS have given written consent for genetic samples and clinical data to be provided for JaCALS and its collaborations. In the patients of genetic testing at Niigata University, written consent was obtained to use genetic information for research purposes. Written informed consent for autopsy cases, including the use of tissues for research purposes, was obtained from the families of the patients.
: Not applicable.
: The authors declare no competing interests.
